Leponex (Clozapine)

• Leponex (clozapine) is used in the management of severe psychotic disorders that are unresponsive to standard therapy.
• Treatment‑resistant schizophrenia: improves psychotic symptoms and reduces relapse risk.
• Schizoaffective disorder: stabilizes mood and psychotic features.
• Suicidal behavior in schizophrenia: lowers incidence of suicide attempts.

• Clozapine acts primarily as an antagonist at dopamine D2 and serotonin 5‑HT2A receptors, while also modulating D4, 5‑HT2C, α1‑adrenergic and muscarinic receptors. This broad receptor profile balances dopaminergic and serotonergic neurotransmission, leading to reduction of positive and negative schizophrenia symptoms and providing a unique anti‑suicidal effect.

Clozapine may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Sedation: feeling unusually sleepy or drowsy.
• Weight gain: increase in body weight over time.
• Drooling (sialorrhea): excess saliva production.
• Constipation: reduced bowel movements.
• Tachycardia: elevated heart rate.

Serious or Rare Side Effects

• Agranulocytosis: severe drop in white blood cells requiring regular monitoring.
• Myocarditis: inflammation of the heart muscle, potentially life‑threatening.
• Seizures: risk of convulsive episodes, especially at higher doses.

• Clozapine requires careful monitoring and specific precautions to ensure patient safety.
• Blood monitoring: weekly complete blood count for the first 6 months, then biweekly/monthly as advised.
• Cardiac assessment: baseline and periodic ECG to detect myocarditis.
• Metabolic monitoring: track weight, glucose, and lipid levels regularly.
• Drug interactions: avoid concurrent use with strong CYP1A2 inhibitors without dose adjustment.
• Pregnancy and lactation: use only if potential benefit outweighs risk; discuss with specialist.
• Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture and light.

Clozapine interacts with several medicines; some combinations must be avoided, while others need close observation.

Major Interactions (Avoid)

• CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin): can cause dangerous clozapine accumulation.
• Concomitant use with other myelosuppressive agents (e.g., carbamazepine): increases risk of agranulocytosis.
• Smoking cessation: abrupt loss of CYP1A2 induction may raise clozapine levels.
• Lithium: additive risk of neutropenia.

Moderate Interactions (Monitor Closely)

• CYP1A2 inducers (e.g., carbamazepine, smoking): may reduce efficacy, dose adjustment may be needed.
• Benzodiazepines: may enhance sedation and respiratory depression.
• Anticholinergic agents: can worsen constipation and urinary retention.